When is the new Immutep patent scheduled to expire?

The newly granted United States patent held by Immutep (ASX:IMM) is scheduled to expire on 20 January 2036. As detailed in image_6f1f1d.png, this intellectual property protects methods for treating cancer by administering eftilagimod alfa with anti-PD-1 or anti-PD-L1 antibodies.

How did the market react to the Immutep patent announcement?

Following the patent announcement, the Immutep (ASX:IMM) share price closed down at $0.055. This market movement occurred immediately after the biotechnology company released the details of its expanded United States patent portfolio.

What is the strategic purpose behind the expanded Immutep patent portfolio?

Immutep (ASX:IMM) stated that the expanded intellectual property estate is designed to support its future clinical development pathways and business development opportunities.

What are the current cash reserves held by Immutep?

Immutep (ASX:IMM) reported holding cash and term deposits of approximately $110.6 million at the end of March 2026. These reserves remain available to fund operations following the company's previous decision to discontinue its Phase III TACTI-004 lung cancer trial during that same month.

Image for illustrative purposes only. Not a real photo.

Immutep secures USPTO patent for cancer treatment anew

Written by Mahathir BayenaPublished Jul 14, 2026, 5:59 AM

The United States Patent and Trademark Office granted Immutep a fourth patent for its combination cancer treatment.
The company's share price closed down at $0.055 following the market announcement.
The expanded intellectual property portfolio aims to protect future clinical development and business opportunities.

Immutep (ASX:IMM) has secured United States patent number 12,673,088 for its cancer immunotherapy combination treatments.

This new intellectual property follows previous related patent grants issued in December 2020, March 2021, and June 2023.

"This expanded IP estate supports future development pathways and business development opportunities," said Immutep CEO Marc Voigt.

The newly granted patent is scheduled to expire on Jan. 20, 2036.

Following the announcement the Immutep share price was down at $0.055.

The company previously discontinued its Phase III TACTI-004 lung cancer trial in March after an interim futility analysis.

The business reported holding cash and term deposits of approximately $110.6 million at the end of March.